GMED Stock Overview
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Globus Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$51.44 |
| 52 Week High | US$62.88 |
| 52 Week Low | US$43.39 |
| Beta | 1.1 |
| 1 Month Change | 0.57% |
| 3 Month Change | -4.28% |
| 1 Year Change | -10.79% |
| 3 Year Change | -28.30% |
| 5 Year Change | 16.54% |
| Change since IPO | 281.04% |
Recent News & Updates
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Apr 08
Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly
Mar 20Recent updates
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Apr 08Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly
Mar 20Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock
Feb 27Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?
Feb 09Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings
Jan 17Globus Medical: Merger Overhang Lingering
Nov 27Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?
Nov 14Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?
Oct 27Globus Medical: Almost Having My Back
Sep 13Globus Medical: Slightly Too Pricey Right Now
Aug 07Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Jul 18Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Jul 11Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching
Jun 18Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Apr 09What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?
Mar 22Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?
Feb 24Globus Medical Q4 2022 Earnings Preview
Feb 20Globus Medical: An Impressive Long-Term Revenue Growth Play
Jan 08Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
Dec 22Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends
Dec 01Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line
Nov 08A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)
Oct 15Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact
Sep 02Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Sep 02Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?
Aug 11Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective
Jun 05Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital
May 24Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
May 06An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 22% Undervalued
Mar 14Globus Medical Continues To Flex Its Innovation Muscles To Drive Share Growth
Mar 01Globus Medical's (NYSE:GMED) Performance Is Even Better Than Its Earnings Suggest
Feb 24Returns On Capital At Globus Medical (NYSE:GMED) Paint A Concerning Picture
Feb 08Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Jan 21Are Globus Medical, Inc. (NYSE:GMED) Investors Paying Above The Intrinsic Value?
Nov 28Returns On Capital At Globus Medical (NYSE:GMED) Paint A Concerning Picture
Nov 10At US$76.32, Is Globus Medical, Inc. (NYSE:GMED) Worth Looking At Closely?
Oct 19Shareholder Returns
| GMED | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.4% | 1.2% |
| 1Y | -10.8% | -0.7% | 24.7% |
Return vs Industry: GMED underperformed the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: GMED underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| GMED volatility | |
|---|---|
| GMED Average Weekly Movement | 3.4% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GMED has not had significant price volatility in the past 3 months.
Volatility Over Time: GMED's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 5,000 | Dan Scavilla | www.globusmedical.com |
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants.
Globus Medical, Inc. Fundamentals Summary
| GMED fundamental statistics | |
|---|---|
| Market cap | US$6.94b |
| Earnings (TTM) | US$122.87m |
| Revenue (TTM) | US$1.57b |
56.7x
P/E Ratio4.4x
P/S RatioIs GMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMED income statement (TTM) | |
|---|---|
| Revenue | US$1.57b |
| Cost of Revenue | US$476.52m |
| Gross Profit | US$1.09b |
| Other Expenses | US$969.09m |
| Earnings | US$122.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 69.62% |
| Net Profit Margin | 7.83% |
| Debt/Equity Ratio | 10.4% |
How did GMED perform over the long term?
See historical performance and comparison